Publications

Find coverage of the latest original articles on scleroderma, focusing on those with data on therapeutic interventions and those that have clinical impact.

Publications

June 2025

View Slides

Comparative efficacy of immunosuppressive therapies in the treatment of diffuse cutaneous systemic sclerosis

ACR Open Rheumatol 2025;7:e70004 DOI: 10.1002/acr2.70004.

White et al. report a post hoc analysis of the RESOLVE-1 trial comparing immunosuppressive therapies in diffuse cutaneous systemic sclerosis (dcSSc), finding numerically greater improvement in modified Rodnan skin score and stabilisation of lung function with mycophenolate mofetil (MMF), particularly in patients with early-stage disease and anti–topoisomerase 1 antibodies. These findings strongly support MMF as a preferred background therapy in this population.

more…

Keywords:

View Slides

Tocilizumab in systemic sclerosis: A randomised, double-blind, placebo-controlled, Phase 3 trial

Lancet Respir Med 2020;8:963–74 DOI: 10.1016/S2213-2600(20)30318-0.

Khanna et al. evaluated tocilizumab in patients with early diffuse cutaneous systemic sclerosis in the focuSSced trial. The primary endpoint of improved skin fibrosis was not met, but a key secondary outcome showed that tocilizumab significantly preserved lung function compared with placebo.

more…